Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PM-54 by Pharma Mar for Epithelial Ovarian Cancer: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...
PM-54 by Pharma Mar for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to...
PM-54 by Pharma Mar for Esophageal Cancer: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...
PM-54 by Pharma Mar for Non-Small Cell Lung Cancer: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Non-Small Cell Lung Cancer. According to...
PM-54 by Pharma Mar for Malignant Pleural Mesothelioma: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData,...
PM-54 by Pharma Mar for Fallopian Tube Cancer: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...
PM-54 by Pharma Mar for Melanoma: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Melanoma. According to GlobalData, Phase I...
PM-54 by Pharma Mar for Small-Cell Lung Cancer: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...